2023年CSCO指南更新解读:Ⅳ期驱动基因阴性非小细胞肺癌诊疗  

Interpretation of updated 2023 CSCO guidelines: diagnosis and treatment of stage Ⅳ driver-gene negativenon-small-cell lung cancer

作　　者：智欣欣 任胜祥[1,2] Zhi Xinxin;Ren Shengxiang(Tongji University School of Medicine,Shanghai 200092,China;Department of Medical Oncology,Shanghai Pulmonary Hospital,Tongji University School of Medicine,Shanghai 200433,China)

机构地区：[1]同济大学医学院,上海200092 [2]同济大学附属上海市肺科医院肿瘤科,上海200433

出　　处：《实用肿瘤杂志》2023年第5期421-426,共6页Journal of Practical Oncology

基　　金：国家自然科学基金项目(82172869,81972167);上海市“科技创新行动计划”优秀学术/技术带头人计划项目(21XD1423200)。

摘　　要：驱动基因阴性非小细胞肺癌的既往标准治疗方案是以铂类药物为基础的双药化疗。抗血管药物和免疫抑制剂的发展给这类患者提供了更多精准化诊疗选择。《中国临床肿瘤学会(CSCO)非小细胞肺癌诊疗指南2023》已于4月在广州更新发布。本文就新版指南对Ⅳ期驱动基因阴性非小细胞肺癌治疗部分的更新进行解读并对未来探索方向进行梳理,为临床诊疗提供参考。The standard of care for non-small-cell lung cancer(NSCLC)without driver mutation has been platinum-based chemotherapy,and the development of antiangiogenic therapy and immune checkpoint inhibitors has provided more precise treatment options for these patients.The 2023 edition of the Chinese Society of Clinical Oncology(CSCO)guidelines for the diagnosis and treatment of NSCLC has been updated and released in Guangzhou in April.This article interprets the updated guidelines on the treatment of stageⅣdriver-gene negative NSCLC and sorts out the direction of future exploration to provide recommendation options for clinical diagnosis and treatment.

关 键 词：非小细胞肺癌 驱动基因阴性 中国临床肿瘤学会 指南解读 

分 类 号：R734.2[医药卫生—肿瘤]